A recent study published in The Lancet Regional Health - Southeast Asia journal indicates that a higher dose of the COVID-19 drug, dexamethasone, may have varying effects for patients in India compared to those in Europe. The research focused on assessing the efficacy of a robust dose of dexamethasone in treating COVID-19 patients, considering factors such as patient differences and health systems.
